Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DA-5209 (Edoxaban) vs Lixiana in Healthy Volunteers
NCT04671316Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edoxaban in deep vein thrombosis (DVT), pulmonary embolism (PE) and stroke (6 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the plasma Concentration versus time curve from time 0 to last measurable concentration at 48 hours and Peak Plasma Concentration at 48 hours. Started Nov 2020; status: completed.
02
Drugs
edoxaban
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)stroke
Beyond the preview
Go deeper on NCT04671316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671316.